2
3
4
5
6
7 LONG TITLE
8 Committee Note:
9 The Health and Human Services Interim Committee recommended this bill.
10 Legislative Vote: 13 voting for 0 voting against 4 absent
11 General Description:
12 This bill amends the list of controlled substances and the composition of the Controlled
13 Substances Advisory Committee.
14 Highlighted Provisions:
15 This bill:
16 ▸ adds a substance to the listed controlled substances in the Utah Controlled
17 Substances Act;
18 ▸ amends the composition of the Controlled Substances Advisory Committee; and
19 ▸ makes technical changes.
20 Money Appropriated in this Bill:
21 None
22 Other Special Clauses:
23 None
24 Utah Code Sections Affected:
25 AMENDS:
26 58-37-4.2, as last amended by Laws of Utah 2018, Chapter 146
27 58-38a-201, as last amended by Laws of Utah 2011, Chapter 60
28 58-38a-202, as last amended by Laws of Utah 2011, Chapter 60
29
30 Be it enacted by the Legislature of the state of Utah:
31 Section 1. Section 58-37-4.2 is amended to read:
32 58-37-4.2. Listed controlled substances.
33 The following substances, their analogs, homologs, and synthetic equivalents are listed
34 controlled substances:
35 (1) AB-001;
36 (2) AB-PINACA;
37 N-[1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide;
38 (3) AB-FUBINACA; N-[1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)
39 methyl]-1H-indazole-3-carboxamide;
40 (4) AB-CHMINACA
41 (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);
42 (5) ADB-CHMINACA (N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
43 (cyclohexylmethyl)indazole-3-carboxamide);
44 (6) ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1oxobutan-2-yl)-1-
45 (4-fluorobenzyl)-1H-indazole-3-caboxamide);
46 (7) AKB48;
47 (8) alpha-Pyrrolidinohexanophenone (alpha-PHP)
48 (1-Phenyl-2-(pyrrolidin-1-yl)hexan-1-one);
49 (9) alpha-Pyrrolidinovalerophenone (alpha-PVP);
50 (10) AM-694 (1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone);
51 (11) AM-1248;
52 (12) AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole);
53 (13) AM-2233;
54 (14) AM-679;
55 (15) A796,260;
56 (16) Butylone;
57 (17) CP 47,497 and its C6, C8, and C9 homologs (2-[(1R,3S)-3-hydroxycyclohexyl]
58 -5-(2-methyloctan-2-yl)phenol);
59 (18) Diisopropyltryptamine (DiPT);
60 (19) Ethylone;
61 (20) Ethylphenidate;
62 (21) Fluoroisocathinone;
63 (22) Fluoromethamphetamine;
64 (23) Fluoromethcathinone;
65 (24) FUB-AMB; methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)valinate;
66 (25) HU-210; (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
67 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
68 (26) HU-211; Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
69 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
70 (27) JWH-015; (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone;
71 (28) JWH-018; Naphthalen-1-yl-(pentylindol-3-yl)methanone {also known as
72 1-Pentyl-3-(1-naphthoyl)indole};
73 (29) JWH-019; 1-hexyl-3-(1-naphthoyl)indole;
74 (30) JWH-073; Naphthalen-1-yl(1-butylindol-3-yl)methanone {also known as
75 1-Butyl-3-(1-naphthoyl)indole};
76 (31) JWH-081; 4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone;
77 (32) JWH-122; CAS#619294-47-2; (1-Pentyl-3-(4-methyl-1-naphthoyl)indole);
78 (33) JWH-200; 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
79 (34) JWH-203; 1-pentyl-3-(2-chlorophenylacetyl)indole;
80 (35) JWH-210; 4-ethyl-1-naphthalenyl(1-pentyl-1H-indol-3-yl)-methanone;
81 (36) JWH-250; 1-pentyl-3-(2-methoxyphenylacetyl)indole;
82 (37) JWH-251; 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone;
83 (38) JWH-398; 1-pentyl-3-(4-chloro-1-naphthoyl)indole;
84 (39) MAM-2201;
85 (40) MAM-2201;
86 (1-(5-fluoropentyl)-1H-indol-3-yl)(4-ethyl-1-naphthalenyl)-methanone;
87 (41) Methoxetamine;
88 (42) Naphyrone;
89 (43) PB-22; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester;
90 (44) Pentedrone;
91 (45) Pentylone;
92 (46) RCS-4; 1-pentyl-3-(4-methoxybenzoyl)indole;
93 (47) RCS-8; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole {also known as
94 BTW-8 and SR-18};
95 (48) STS-135;
96 (49) UR-144;
97 (50) UR-144 N-(5-chloropentyl) analog;
98 (51) XLR11;
99 (52) 2C-C;
100 (53) 2C-D;
101 (54) 2C-E;
102 (55) 2C-H;
103 (56) 2C-I;
104 (57) 2C-N;
105 (58) 2C-P;
106 (59) 2C-T-2;
107 (60) 2C-T-4;
108 (61) 2NE1;
109 (62) 25I-NBOMe;
110 (63) 2,5-Dimethoxy-4-chloroamphetamine (DOC);
111 (64) 4-Fluoro MDMB-BUTINACA (Methyl
112 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate);
113 [
114 [
115 [
116 [
117 [
118 [
119 [
120 1-(5-flouropentyl)-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3- carboxamide;
121 [
122 N-{[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl}-3-methyl-valinate);
123 [
124 N-{[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl}valinate);
125 [
126 8-quinolinyl ester;
127 [
128 [
129 [
130 methyl]ethanamine;
131 [
132 methyl]ethanamine; and
133 [
134 2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine.
135 Section 2. Section 58-38a-201 is amended to read:
136 58-38a-201. Controlled Substances Advisory Committee.
137 There is created within the Division of Occupational and Professional Licensing the
138 Controlled Substances Advisory Committee. The committee consists of:
139 (1) the director of the Department of Health or the director's designee;
140 (2) the State Medical Examiner or the examiner's designee;
141 (3) the commissioner of the Department of Public Safety or the commissioner's
142 designee;
143 (4) the director of the Bureau of Forensic Services created in Section 53-10-401, or the
144 director's designee;
145 (5) the director of the Utah Poison Control Center or the director's designee;
146 [
147 designated by that board;
148 [
149 designated by that board;
150 [
151 Board and is designated by that board;
152 [
153 appointed by the governor;
154 [
155 appointed by the governor;
156 [
157 by the governor;
158 [
159 designated by that association;
160 [
161 state, to be appointed by the governor;
162 [
163 practicing in this state, to be appointed by the governor; and
164 [
165 Section 3. Section 58-38a-202 is amended to read:
166 58-38a-202. Terms of committee service.
167 (1) (a) Members of the advisory committee shall serve terms of four years, except that
168 the members under Subsections 58-38a-201(1), (2), [
169 terms as appointed officials.
170 (b) Vacancies in the committee occurring otherwise than by the expiration of a term
171 shall be filled for the unexpired term in the same manner as original appointments.
172 (2) A member may not receive compensation or benefits for the member's service, but
173 may receive per diem and travel expenses in accordance with:
174 (a) Section 63A-3-106;
175 (b) Section 63A-3-107; and
176 (c) rules made by the Division of Finance pursuant to Sections 63A-3-106 and
177 63A-3-107.
178 (3) (a) The director of the Department of Health, or the director's designee, is the chair
179 of the committee.
180 (b) The advisory committee meets at the call of the chair or at the call of a majority of
181 the committee members.
182 (c) The advisory committee meets annually and more often as required to carry out its
183 duties under this chapter.
184 (d) Seven members of the advisory committee constitute a quorum.
185 (e) Action by the committee requires a majority vote of a quorum.